Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 24Carboplatin 18Bevacizumab 14Cisplatin 12pembrolizumab 7fluzoparib 7Drug Therapy 7Radiotherapy 6camrelizumab 5apatinib 5Topotecan 5Magnetic Resonance Spectroscopy 5Injections 5liposomal doxorubicin 4lenvatinib 4famitinib 4Tirzepatide 4Specimen Handling 4Platinum 4Observation 4Gemcitabine 4Brachytherapy 4toripalimab 3olaparib 3dostarlimab 3anlotinib 3Watchful Waiting 3Therapeutics 3Surveys and Questionnaires 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Angiogenesis Inhibitors × Gynecologic × Clear all
NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
44 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡